B+L launches PureVision2 Multi-Focal

Article

Bausch + Lomb introduced PureVision2 Multi-Focal (balafilcon A) monthly silicone hydrogel multifocal contact lenses at the American Academy of Optometry meeting. Featuring a next-generation 3-zone progressive design, these lenses are designed to improve near and intermediate vision while providing excellent distance clarity.

 

Seattle-Bausch + Lomb introduced PureVision2 Multi-Focal (balafilcon A) monthly silicone hydrogel multifocal contact lenses at the American Academy of Optometry meeting. Featuring a next-generation 3-zone progressive design, these lenses are designed to improve near and intermediate vision while providing excellent distance clarity.

The lens design allows for a more predictable, quick fit for the eyecare professional. According to the company, PureVision2 Multi-Focal helped maintain clear near, intermediate, and distance vision in real-world conditions.

The lenses are approved for extended wear up to 30 days in powers ranging from +6.00 D to –10.00 D in 0.25 D steps. Low add power helps patients needing 0.75 D to 1.50 D of near power, while the high add power addresses needs of 1.75 D to 2.50 D. Base curve is 8.6 mm, and diameter is 14.0 mm.

“We know that consistent, crisp, clear vision at all distances can be a challenge for people with presbyopia. These new lenses will provide that consistency whether viewing a screen on your mobile phone or a screen at the cinema,” said Joseph Barr, OD, MS, vice president, Medical Affairs, Pharmaceuticals, Vision Care, Bausch + Lomb. “We’re optimistic that the combination of a streamlined fit and a satisfied patient will make this lens a favorite for the eyecare professional.”

 

Recent Videos
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
Sherrol Reynolds, OD, FAAO, said that multimodel imaging has been a game changer in assessing the choroidal function and structural changes in various disease conditions.
Susan Gromacki, OD, FAAO, FSLS, provides key takeaways from this year's American Academy of Optometry symposium genetics and the cornea.
Roya Attar gives an overview of her presentation, "Decoding the Retina: The Value of Genetic Testing In Inherited Disorders," presented with Mohammad Rafieetary, OD, FAAO, FORS, ABO, ABCMO.
Ian Ben Gaddie, OD, FAAO, outlines key findings from a recent study evaluating lotilaner in patients with Demodex blepharitis and meibomian gland dysfunction.
© 2024 MJH Life Sciences

All rights reserved.